TORONTO, April 3, 2023 /PRNewswire/ - Greenbrook TMS Inc. (NASDAQ: GBNH) ("Greenbrook" or the "Company") today announced that the Company has amended its amended and restated master sales agreement ...

Transcranial Magnetic Stimulation (TMS) is a non-invasive treatment for depression when medications aren't working.

Transcranial magnetic stimulation (TMS) has been an FDA-cleared therapy for treatment-resistant depression since 2008, but the equipment has historically been too expensive, large, and complex for ...

NeuroStar Advanced Therapy is a transcranial magnetic stimulation system that uses magnetic fields to induce neural activity in the cerebral cortex. The Food and Drug Administration (FDA) has cleared ...

Patient Receives Depression Treatment Using neurocare’s Apollo TMS System A patient undergoing Transcranial Magnetic Stimulation (TMS) therapy for depression with neurocare’s Apollo TMS System in a ...

Neuronetics said the FDA cleared its transcranial magnetic stimulation (TMS) device, NeuroStar, as an adjunct therapy for the first-line treatment of major depressive disorder in individuals ages 15 ...

Credit: BrainsWay. The outpatient procedure provides noninvasive magnetic stimulation through a cushioned helmet to induce electrical currents in localized regions of the prefrontal cortex. Real-world ...

83% of patients who complete Transcranial Magnetic Stimulation treatment experience measurable relief and 62% experience full remission of depression symptoms The expanded label positions Neuronetics' ...

Please provide your email address to receive an email when new articles are posted on . Deep TMS has received expanded indication for the treatment of major depressive disorder in patients aged 22 to ...

The US Food and Drug Administration (FDA) granted 510K clearance to market a new transcranial magnetic stimulation (TMS) device, the MagVita TMS Therapy system from MagVenture, for treatment of adults ...